---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-044533"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:15:06.290991+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Indaptus Q3 2024: EPS -$0.32, cash $7.4M; Decoy20 Phase 1 expands with BeiGene deal

## Summary
- Q3 2024 net loss $0.32 per share (vs $0.47 loss in Q3 2023); nine-month loss $1.23 per share (vs $1.36 loss).
- Cash and equivalents $7.4M at Sep 30, 2024, down from $13.4M at Dec 31, 2023; cash runway into Q1 2025.
- Clinical supply agreement with BeiGene to combine Decoy20 with tislelizumab (anti-PD-1) for advanced solid tumors.
- Phase 1 trial of Decoy20 now allows unrestricted enrollment for weekly dosing at lower dose; well tolerated.
- R&D expenses decreased to $1.5M in Q3 2024 from $2.2M YoY; completed $3M registered direct offering in August 2024.

## SEC filing metadata
- accession: 0001493152-24-044533
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315224044533/0001493152-24-044533-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315224044533/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-044533
- JSON: https://secwatch.observer/filing/0001493152-24-044533.json
- Plain text: https://secwatch.observer/filing/0001493152-24-044533.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.